No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
surufatinib Sensitive: A1 - Approval
|
surufatinib Sensitive: A1 - Approval
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
sunitinib Sensitive: A1 - Approval
|
sunitinib Sensitive: A1 - Approval
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval
|
lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
sunitinib Sensitive: A1 - Approval
|
sunitinib Sensitive: A1 - Approval
|
VHL mutation
|
Neuroendocrine Tumor
|
VHL mutation
|
Neuroendocrine Tumor
|
belzutifan Sensitive: A1 - Approval
|
belzutifan Sensitive: A1 - Approval
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
octreotide Sensitive: A2 - Guideline
|
octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
SSTR positive
|
Neuroendocrine Tumor
|
SSTR positive
|
Neuroendocrine Tumor
|
lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline
|
lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline
|
SSTR positive
|
Neuroendocrine Tumor
|
SSTR positive
|
Neuroendocrine Tumor
|
octreotide Sensitive: A2 - Guideline
|
octreotide Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
carboplatin + etoposide IV Sensitive: A2 - Guideline
|
carboplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
temozolomide + capecitabine Sensitive: A2 - Guideline
|
temozolomide + capecitabine Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Neuroendocrine Tumor
|
MSI-H/dMMR
|
Neuroendocrine Tumor
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
FOLFIRINOX Sensitive: A2 - Guideline
|
FOLFIRINOX Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
carboplatin + irinotecan Sensitive: A2 - Guideline
|
carboplatin + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
FOLFIRI Sensitive: A2 - Guideline
|
FOLFIRI Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
5-fluorouracil + streptozocin Sensitive: A2 - Guideline
|
5-fluorouracil + streptozocin Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
doxorubicin hydrochloride + streptozocin Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + streptozocin Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
streptozocin Sensitive: A2 - Guideline
|
streptozocin Sensitive: A2 - Guideline
|
TMB-H
|
Neuroendocrine Tumor
|
TMB-H
|
Neuroendocrine Tumor
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
FAS Sensitive: A2 - Guideline
|
FAS Sensitive: A2 - Guideline
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
carboplatin + cabazitaxel Sensitive: A2 - Guideline
|
carboplatin + cabazitaxel Sensitive: A2 - Guideline
|
SSTR positive
|
Neuroendocrine Tumor
|
SSTR positive
|
Neuroendocrine Tumor
|
lutetium Lu 177 dotatate Sensitive: B - Late Trials
|
lutetium Lu 177 dotatate Sensitive: B - Late Trials
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
RET fusion
|
Neuroendocrine Tumor
|
RET fusion
|
Neuroendocrine Tumor
|
selpercatinib Sensitive: C1 - Off-label
|
selpercatinib Sensitive: C1 - Off-label
|
ALK positive
|
Neuroendocrine Tumor
|
ALK positive
|
Neuroendocrine Tumor
|
alectinib Sensitive: C1 - Off-label
|
alectinib Sensitive: C1 - Off-label
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
cetuximab + encorafenib Sensitive: C1 - Off-label
|
cetuximab + encorafenib Sensitive: C1 - Off-label
|
DLL3 overexpression
|
Neuroendocrine Tumor
|
DLL3 overexpression
|
Neuroendocrine Tumor
|
rovalpituzumab tesirine Sensitive: C2 – Inclusion Criteria
|
rovalpituzumab tesirine Sensitive: C2 – Inclusion Criteria
|
SSTR2 positive
|
Neuroendocrine Tumor
|
SSTR2 positive
|
Neuroendocrine Tumor
|
PEN-221 Sensitive: C2 – Inclusion Criteria
|
PEN-221 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Neuroendocrine Tumor
|
PD-L1 expression
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Neuroendocrine Tumor
|
PD-L1 expression
|
Neuroendocrine Tumor
|
PDR001 Sensitive: C3 – Early Trials
|
PDR001 Sensitive: C3 – Early Trials
|
mTOR expression + RPS6KB1 expression
|
Neuroendocrine Tumor
|
mTOR expression + RPS6KB1 expression
|
Neuroendocrine Tumor
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
MGMT deletion
|
Neuroendocrine Tumor
|
MGMT deletion
|
Neuroendocrine Tumor
|
temozolomide Sensitive: C3 – Early Trials
|
temozolomide Sensitive: C3 – Early Trials
|
TMB-H
|
Neuroendocrine Tumor
|
TMB-H
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
FGFR4 G388R
|
Neuroendocrine Tumor
|
FGFR4 G388R
|
Neuroendocrine Tumor
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
CA9 overexpression
|
Neuroendocrine Tumor
|
CA9 overexpression
|
Neuroendocrine Tumor
|
doxorubicin hydrochloride Resistant: C3 – Early Trials
|
doxorubicin hydrochloride Resistant: C3 – Early Trials
|
FLT4 T494A
|
Neuroendocrine Tumor
|
FLT4 T494A
|
Neuroendocrine Tumor
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
FLT4 R1324L
|
Neuroendocrine Tumor
|
FLT4 R1324L
|
Neuroendocrine Tumor
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
VHL mutation
|
Neuroendocrine Tumor
|
VHL mutation
|
Neuroendocrine Tumor
|
PT2385 Sensitive: C3 – Early Trials
|
PT2385 Sensitive: C3 – Early Trials
|
TP53 mutation
|
Neuroendocrine Tumor
|
TP53 mutation
|
Neuroendocrine Tumor
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
SSTR5 expression
|
Neuroendocrine Tumor
|
SSTR5 expression
|
Neuroendocrine Tumor
|
octreotide Sensitive: C3 – Early Trials
|
octreotide Sensitive: C3 – Early Trials
|
SSTR2 expression
|
Neuroendocrine Tumor
|
SSTR2 expression
|
Neuroendocrine Tumor
|
octreotide Sensitive: C3 – Early Trials
|
octreotide Sensitive: C3 – Early Trials
|
SSTR Expression
|
Neuroendocrine Tumor
|
SSTR Expression
|
Neuroendocrine Tumor
|
ORM-2110 Sensitive: C3 – Early Trials
|
ORM-2110 Sensitive: C3 – Early Trials
|
MSI-H/dMMR + PD-L1 expression
|
Neuroendocrine Tumor
|
MSI-H/dMMR + PD-L1 expression
|
Neuroendocrine Tumor
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
ARID1A mutation
|
Neuroendocrine Tumor
|
ARID1A mutation
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
TMB-L
|
Neuroendocrine Tumor
|
TMB-L
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
TGFB1-H
|
Neuroendocrine Tumor
|
TGFB1-H
|
Neuroendocrine Tumor
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
PD-L1-H
|
Neuroendocrine Tumor
|
PD-L1-H
|
Neuroendocrine Tumor
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
PD-L1 expression
|
Neuroendocrine Tumor
|
PD-L1 expression
|
Neuroendocrine Tumor
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
toripalimab + surufatinib Sensitive: C3 – Early Trials
|
MGMT promoter methylation
|
Neuroendocrine Tumor
|
MGMT promoter methylation
|
Neuroendocrine Tumor
|
temozolomide Sensitive: C3 – Early Trials
|
temozolomide Sensitive: C3 – Early Trials
|
EWSR1-CREB1 fusion
|
Neuroendocrine Tumor
|
EWSR1-CREB1 fusion
|
Neuroendocrine Tumor
|
crizotinib + pazopanib Sensitive: C4 – Case Studies
|
crizotinib + pazopanib Sensitive: C4 – Case Studies
|
MUC16 elevation
|
Neuroendocrine Tumor
|
MUC16 elevation
|
Neuroendocrine Tumor
|
TC Sensitive: C4 – Case Studies
|
TC Sensitive: C4 – Case Studies
|
TMB-L + PD-L1 expression
|
Neuroendocrine Tumor
|
TMB-L + PD-L1 expression
|
Neuroendocrine Tumor
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
pazopanib Resistant: C4 – Case Studies
|
pazopanib Resistant: C4 – Case Studies
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
trametinib + vemurafenib Sensitive: C4 – Case Studies
|
trametinib + vemurafenib Sensitive: C4 – Case Studies
|
BRCA2 exon 11 deletion
|
Neuroendocrine Tumor
|
BRCA2 exon 11 deletion
|
Neuroendocrine Tumor
|
olaparib Resistant: C4 – Case Studies
|
olaparib Resistant: C4 – Case Studies
|
ETV6-NTRK3 fusion
|
Neuroendocrine Tumor
|
ETV6-NTRK3 fusion
|
Neuroendocrine Tumor
|
entrectinib Sensitive: C4 – Case Studies
|
entrectinib Sensitive: C4 – Case Studies
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF inhibitor Sensitive: C4 – Case Studies
|
BRAF inhibitor Sensitive: C4 – Case Studies
|
EML4-ALK fusion
|
Neuroendocrine Tumor
|
EML4-ALK fusion
|
Neuroendocrine Tumor
|
lorlatinib Sensitive: C4 – Case Studies
|
lorlatinib Sensitive: C4 – Case Studies
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
mFOLFOX6 Resistant: C4 – Case Studies
|
mFOLFOX6 Resistant: C4 – Case Studies
|
BRAF V600E
|
Neuroendocrine Tumor
|
BRAF V600E
|
Neuroendocrine Tumor
|
cisplatin + irinotecan Resistant: C4 – Case Studies
|
cisplatin + irinotecan Resistant: C4 – Case Studies
|
CEACAM5 expression
|
Neuroendocrine Tumor
|
CEACAM5 expression
|
Neuroendocrine Tumor
|
IMMU-130 Sensitive: D – Preclinical
|
IMMU-130 Sensitive: D – Preclinical
|
TYRO3 mutation + ALK mutation
|
Neuroendocrine Tumor
|
TYRO3 mutation + ALK mutation
|
Neuroendocrine Tumor
|
sunitinib Sensitive: D – Preclinical
|
sunitinib Sensitive: D – Preclinical
|
TYRO3 mutation + ALK mutation
|
Neuroendocrine Tumor
|
TYRO3 mutation + ALK mutation
|
Neuroendocrine Tumor
|
crizotinib + sunitinib Sensitive: D – Preclinical
|
crizotinib + sunitinib Sensitive: D – Preclinical
|
TYRO3 mutation + ALK mutation
|
Neuroendocrine Tumor
|
TYRO3 mutation + ALK mutation
|
Neuroendocrine Tumor
|
crizotinib Resistant: D – Preclinical
|
crizotinib Resistant: D – Preclinical
|